Royal DSM, the global Life Sciences and Materials Sciences company, has successfully issued a €300 million 1.75% bond due 2019.
The proceeds will be used to refinance the $150 million US Private Placement that matured in October 2013 and to refinance some short term commercial paper with a longer maturity.
The terms are laid down in the EUR 4 billion Debt Issuance Program of Royal DSM, the final terms and the supplements thereto, which are available on the Investor Relations website.
The re-offer price was 99.96%. Based on this price the yield is 1.7570%. The bond will be listed on Euronext Amsterdam shortly.
This release does not constitute an offer or an invitation to subscribe for or purchase any securities. The notes are being offered only by means of a prospectus.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found www.dsm.com.
For more information:
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
HUG#1741086